Besides Remdesivir, These 2 COVID-19 Treatments Could Have Promise

In the mission to defeat COVID-19, scientists from all over the world are racing two develop two avenues of treatment: an effective therapy, and eventually a vaccine. This is so important to the investing world because we won't be able to go back to a 100% economy, with travel and leisure industries back to normal, until we have a vaccine. In the meantime, effective testing and treatment could help consumers get confident enough to go back to some businesses, allowing the economy to open up more than it has already.

Most experts put the timeline for a vaccine at 18 months, though it might be either a bit shorter or longer than that. Until then, many market participants have focused on Remdesivir, a drug from Gilead (NASDAQ: GILD). There have been conflicting reports around Remdesivir as of late, with the World Health Organization accidentally posting a Chinese study saying that Remdesivir wasn't materially effective. However, Gilead chimed in the next day disputing the results. Apparently, the Chinese study was stopped because of low enrollment, and a Gilead spokesperson said the results of the trial were actually encouraging, particularly for patients treated early.

While Remdesivir could be helpful, it also isn't the only game in town. Recently, two new avenues of treatment have come to light that could prove helpful in mitigating the effects of coronavirus until we get a vaccine.

Continue reading

Source Fool.com